This might be a NO NO in terms of the intention of
the creation of this board ...
If it is - this will be the last post of this nature ....
I'm gonna call this the BioContest Newsletter Report
#1 ....
Its purpose is to re-post 1 significant post about
one of the stocks in the CONSENSUS portfolio ...
and thereby give all contestants knowledge about it
in case they missed it ....
the post was really a conversation between Peter and
Zeta ....
the stock they talk about is NOT in my contest portfolio
but I do think all contestants would like to read this
info ..... i.e. be aware of it ...
The bold letters are mine .....
CR means Complete Response (I think)
re:TELK
Peter posted this ...
<<<<<<<<<<<<<
Nope, that link doesn't work. But I have access, and I really like this quote:
One patient who presented with platinum and paclitaxel
refractory disease achieved a durable CR. This
patient had stage IV ovarian cancer and was treated
by inadequate debulking surgery followed by carboplatin
and paclitaxel. She progressed during her sixth
cycle, exhibiting measurable bulky (5 cm) disease in
liver and spleen (target lesions), ascites, and diffuse
abdominal metastases that were nonmeasurable, and
a rising CA125 level of 36.
After two cycles (6 weeks) of TLK286, the patient had a robust PR, and after completing six cycles of TLK286, the patient experienced a confirmed CR. The patient continues in complete remission for more than 3 years and off all therapy for more than 2.5 years
Only one patient, but that's an incredible result on monotherapy.
Peter
<<<<<<<<<<<<<
which was in response to Zeta's post which was ...
>>>>>>>>>>>>>>
Erik, here is the full text of the mono-P2 ovarian study
blackwell-synergy.com
I splurged for the paper..if the link doesn't work, I'll copy/paste..hoping this will work as the tables are good..
Elisabeth
>>>>>>>>>>>>>>
Bottom line, late stage ovarian, paclitaxel fails, and
a single drug pulls her back from oblivion ... and
pulls her ALL THE WAY BACK ....
just gotta love it ...
regards,
John |
